Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
 combination product on 25 May 2016 - EconoTimes)
- The briefing documents posted on FDA's website include results from the two Phase III trials with the lixisenatide/Lantus(r) combination, not previously published
- US regulatory decisions on lixisenatide and the lixisenatide/Lantus(r) combination are expected in July and August 2016, respectively
COPENHAGEN, Denmark, May 23, 2016 -- Zealand announces that the US Food and Drug Administration (FDA) today has made briefing documents on lixisenatide and the lixisenatide/Lantus(r) combination available on its website. The documents relate to the upcoming meeting of the Endocrinologic and Metabolic Drugs Advisory Committee, scheduled by the FDA for 8:00 am to 5:00 pm ET on 25 May 2016 to discuss the New Drug Applications (NDAs) for the two drug products intended for the treatment of adults with Type 2 diabetes. The NDAs were submitted by Sanofi.
The briefing documents contain the key points for discussion at the Advisory Committee meeting and background information on lixisenatide and the lixisenatide/Lantus(r) combination. This include the results from Sanofi's two clinical Phase III trials with the lixisenatide/Lantus(r) combination, LixiLan-L and LixiLan-O, which have not previously been published. The briefing documents can be accessed under the following link: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm491062.htm
Lixisenatide is a once-daily GLP-1 receptor agonist, invented by Zealand and with global development and commercial rights licensed to Sanofi. The lixisenatide/Lantus(r) combination is a fixed-ratio combination of lixisenatide and basal insulin glargine (100 U/mL), developed by Sanofi under the license agreement with Zealand.
Sanofi submitted the US NDA on lixisenatide in July 2015 and it was accepted by the FDA for regulatory review in September 2015. A regulatory decision on lixisenatide is expected in July 2016. In December 2015, Sanofi submitted the US NDA on the lixisenatide/Lantus(r) combination product, redeeming a Priority Review Voucher with the submission. In February the FDA accepted the NDA for priority review with a regulatory decision expected in August 2016.
